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Aim: To assess the challenges, feasibility, and efficacy of device closure of patent ductus arteriosus (PDA) in small
children weighing 610 kg for different types of devices used in an initial experience at Sohag University hospital.
Methods: Between March 2011 and September 2014, 91 patients with PDA underwent transcatheter closure in our
institute, among whom 54 weighed 610 kg. All of these patients underwent transcatheter closure of PDA using
either a Cook Detachable Coil, PFM Nit-Occlud, or Amplatzer duct occluder. A retrospective review of the treatment
results and adverse events was performed.
Results: Successful device placement was achieved in 53/54 small children (98.1%). The median minimum PDA
diameter was 2.4 mm [interquartile range (IQR, 1.8–3.5 mm), median weight 8 kg (IQR, 7–10 kg), and median age
10 months (IQR, 8–17 months)]. Mild aortic obstruction occurred in one case (1.9%), as the device became displaced
towards the aorta after release. The device embolized in one case (1.9%) and no retrieval attempt was made. Five
cases (9.3%) had minor vascular complications.
Conclusion: With the current availability of devices for PDA closure, transcatheter closure of PDA is considered
safe and efficacious in small children weighing 610 kg with good mid-term outcome. The procedure had a low rate
of high-severity adverse events even with the initial experience of the catheterization laboratory.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Transcatheter occlusion of the patent ductusarteriosus (PDA) using either coils or device
transcatheter therapy is considered to be a well-established procedure both in adults and older
children. Since the first experience of the tran-
scatheter occlusion of PDA by Porstmann et al.
in 1967 [1], technical improvements over the years
have increased the proportion of patients who
undergo successful transcatheter closure [2,3].eCCBY-
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AE Adverse events
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are many problems during performance of tran-
scatheter PDA closure in infants: relatively large
sheath size for small vessels, stiffness of the
delivery system with resultant hemodynamic
instability during device deployment, risk of pro-
trusion of the device into the aorta or pulmonary
artery, poor anchoring or stability within the
PDA, and difficult retrievability [4,19]. The
purpose of this study was to determine efficacy
and safety of transcatheter closure of PDA in
infants weighing <10 kg and mid-term follow-up
of our institution in its initial experience.Figure 1. Descending aortogram showing large tubular type C patent
ductus arteriosus in lateral view.Materials and methods
A total of 91 patients underwent transcatheter
occlusion of PDA at Sohag University Hospital
from April 2011 to September 2013. Among them,
54 (58%) patients (13 male, 38 female), weighing
<10 kg, were included in this retrospective study.
We retrospectively analyzed medical records,
echocardiographic findings, angiographic find-
ings, hemodynamic data, adverse events, and
follow-up results of these patients.
Written consent from parents of patients
included in the study and the approval of ethical
scientific committee of Sohag University Hospital
were obtained.
The patients who were selected for this device
occlusion were those with clinical and echocardio-
graphic features of PDA who weighed 5 kg. These
patients had one or more of the following:
symptoms and signs of cardiac failure requiring
medications, failure to thrive, bounding pulses,
cardiomegaly on chest radiography and at
least moderate dilation of the left atrium and ven-
tricle on two-dimensional echocardiography. Two
patients had a small restrictive perimemberanous
ventricular septal defect (VSD); one patient had
mitral valve prolapse with moderate mitral
regurgitation; and two patients had small ostium
secundum atrial septal defect. Three patients had
genetic syndrome: two patients had Down syn-
drome and the third patient had Turner syndrome.
The patients’ clinical characteristics (age, sex,
and weight) were recorded. Aortic angiogram in
lateral and right anterior oblique views was
performed to evaluate the size, position, and
shape of the duct for appropriately choosing the
occluder device type and size. Hemodynamic data
including pulmonary artery pressure and the
pulmonary-to-systemic flow ratio were recorded.
The technique of device deployment was similar
to that reported in the literature [5,6]. Detachableor PFM coils were used for patients with small
PDAs of 61.5 mm at the narrowest diameter.
Amplatzer duct occluders (ADOs) were used for
PDAs that were >1.5 mm. ADO size selected was
usually 2–3 mm larger than the duct diameter in
children [7]. However, some exceptions to this rule
had to be made due to unavailability of the
devices at the time of procedure. Amplatzer mus-
cular VSD devices (AGA Medical Corporation,
Golden Valley, Minnesota) were used in the one
type C PDA that had long length. After device
deployment in PDA, a second aortic angiogram
was performed 10 min after device deployment
(Figs. 1 and 2). In four patients, the PDA occluders
(ADO I; AGA Medical Corporation, Golden
Valley, Minnesota) were implanted using venous
access only as the arterial line was not accessible.
The angiography for determination of PDA mea-
surements was done by pigtail catheter intro-
duced through PDA from pulmonary artery
(Fig. 3). The position of the occluder was deter-
mined by angiography through the delivery
sheath and by echocardiography.
The fluoroscopy time during the procedure were
identified. The transcatheter occlusion was per-
formed under general anesthesia in our 1st year
of experience, after which the procedure was per-











Figure 2. Descending aortogram showing the Amplatzer muscular
ventricular septal defect in the patent ductus arteriosus position with
foaming through the device.
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Chest radiography and transthoracic echocardio-
graphy were conducted 24 h after the procedure to
evaluate the shape and position of the device.
Patients had follow up in the Pediatric Cardiology
Out-patient Clinic at intervals of 24 h then at
1 month, 6 months, and 12 months after the proce-
dure. Patients were checked clinically for any evi-
dence of cardiac murmur during each follow-up.
Complete echocardiographic data (left pulmonary
artery and aorticDoppler interrogation) in addition
to evaluation for residual shunting was performedFigure 3. Angiography in lateral view performed with the pigtail
catheter introduced through the pulmonary artery and patent ductus
arteriosus. The loop of the catheter is placed in the aortic arch.by using a Vivid S5 (GE health care, Norway)
echocardiography machine (General Electric).Statistical analysis
Univariate analyses were performed using SPSS
Statistics 17.0 (SPSS, Chicago, IL, USA). The
patients’ clinical characteristics and outcome were
expressed as median and interquartile range for
all continuous variables and frequency with per-
centages for categorical variables.Results
The demographic and catheterization data of the
patients undergoing transcatheter closure of PDA
are listed in Table 1. The median pulmonary end
of PDAs was 2.4 mm by angiography. The median
pulmonary-to-systematic flow ratio was 1.9:1. The
mean pulmonary pressure was 28.4 mmHg. The
device was successfully deployed in 53 (98.1%)
patients.
Twenty-four patients had trace angiographic
residual shunt with foaming through the device
with contrast jet. On the following day, this foam-
ing leak disappeared completely in all cases.
The median fluoroscopy time was 18 min and
the median total procedure time was 47 min
(Table 1).
Using the classification adopted by Krichenko
et al. [8], 51 patients had type A (well-defined
ampulla at the aortic end and constriction at pul-
monary artery end), three patients had type E
(long with remote constriction), and one infant
had type C PDA.
In our experience, ADO I was the most common
device used in this study (85.2%). Our protocol inTable 1. Demographic and catheterization data.
Variable Median, IQR (range) or
Number (%)
Age (months) 10 (IQR 8 to 17)
Sex (M/F) (15/39) (27.8%/72.2%)
Weight (kg) 8 (IQR 7 to 10)
Genetic syndromes 3 (5.6%)
Intracardiac disease and PDA 5 (9.3%)
Mean pulmonary artery
pressure (mmHg)
27 (IQR 23 to 31)
Size of pulmonary end of PDA
(mm)
2.4 (IQR 1.8 to 3.5)
Size of aortic ampula of PDA
(mm)
8.5 (IQR 7 to 10.5)
Qp/Qs 1.6/1 (IQR 1.5/1 to 2.3/1)
Fluroscopy time (min) 18 (IQR 16 to 23)
Procedure time 47 (IQR 45 to 49)
Follow up duration (months) 34 (IQR 7 to 34)
Qp/Qs: pulmonary to systematic flow ratio.
Figure 5. Descending aortogram showing an Amplatzer duct occluder
II in the patent ductus arteriosus position with foaming after
deployment.
Table 2. Description of devices used for closure.
Device n Arterial sheath Venous sheath
Coil 4- to 5-F 4- to 6-F
Nit Occlud PFM 4
Detachable Cook 2




ADO114/6 1 4-F 6-F
MVSD 1 5-F 7-F
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large PDA, in contrast the Nit-Occlud PFM (Pfm,
Cologn, Germany) and detachable Cook coils
(Cook Cardiology, Bloomington, IN) were used
in small PDA (Table 2). Amplatzer muscular
VSD occlude 6 mm used in one children who
had PDA type C (Figs. 1 and 2). ADO II was used
in one child who had small type A PDA
(Figs. 4 and 5).
No patient required blood transfusion. All
patients except those who had adverse events,
were discharged home 1 day after the closure
and no patient had residual shunt on color
Doppler echocardiography after 24 h.
Forty-four out of 51 (81.5%) patients had
completed 6-month and 12-month follow-up and
all patients were found to have complete closure
with no evidence of device migration, recanaliza-
tion, thromboembolic episodes, wire fracture,
hemolysis, or endocarditis.Figure 4. Descending aortogram showing small tubular patent ductus
arteriosus size in lateral view.There was no evidence of obstruction of left pul-
monary artery, as confirmed by two-dimensional-
Doppler echocardiography during follow up.
There was flow acceleration in the descending
aorta in one patient on follow-up echocardiogram.
This patient had large tubular PDA (type C),
which was closed using the Amplatzer muscular
VSD 6 mm; the patient weighed 6 kg and was
noted to have a peak velocity in the descending
aorta of 2.8 m/s at the 6-month follow up. This
patient continued to be followed as an outpatient
without further intervention for 2 years.
Adverse events
We used previously established and tested def-
initions for adverse event (AE) severity ranging
from Level 1 to Level 5. For this analysis, clinically
important higher severity AEs were defined as
Levels 3, 4, or 5 AEs [9,10]. One patient (1.9%)
experienced higher severity adverse events dur-
ing the procedure with Amplatzer duct occluder
embolization to the main pulmonary artery. The
patient’s weight was 6 kg, age 9 months, and the
PDA was closed with ADO I size 8/6 mm without
residual shunt in the second aortogram. During
release of device, embolization occurred sponta-
neously. We thought embolization occurred sec-
ondary to increased flow through the PDA with
possible under-sizing of the device. The patient
was referred to surgery for device removal and
ligation of PDA. No catheter retrieval was attempt.
There were five infants who had temporary loss
of femoral arterial for 2 days, which considered a
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Transcatheter closure of PDA has been the
mainstay of treatment in children and adults
[11]. Fortescue et al. presented a retrospective case
series of 1808 patients with transcatheter closure
of PDA in a report published in 2010. Overall
PDA closure rate was 94% and major AEs were
1.5% [12]. There have been only a few minor com-
plications compared with the initial interventional
data [13,14]. Nevertheless, procedure-associated
complications have been described in different
age groups, and they are relatively major in
infants [7,15,16].
In this study, we evaluated 54 small children
who weighed 610 kg and underwent percuta-
neous transcatheter PDA closure during a period
of 42 months, which was the initial experience of
our institution, and found that the high-severity
AE rate (Levels 3, 4, and 5) was 1.9% without any
mortality.
The success rate of PDA closure was 98% in our
experience. This confirms the safety of tran-
scatheter closure of PDA in children weighing
<10 kg. In a previous report by Park et al. [17],
the median age of 115 patients was 8 months and
mean body weight was 7.8 kg. The success rate
was 98%, similar to our results.
El-Said et al. [18] reported a large prospective
multicenter study unbiased to patient or device
selection of transcatheter closure of PDA. The
study evaluated 290 small children of 496 patients;
the success rate of PDA closure was 97–99%. Also,
the rate of high-severity complications of this
study was low (2.2%). AEs were more likely to
occur in young patients (<6 months), and in
patients <6 kg. Among these young patients, there
were three high-severity AEs: device emboliza-
tion, difficulty to arouse after anesthesia and
requiring reintubation, and hypotension requiring
inotrope support.
In Dimas et al.’s multicenter study [19], the age
of the infants studied was younger and their
weights were lower. Successful device placement
was achieved in 58 of 62 patients (94%).
Retrospective review of the four implant failures
in this study revealed favorable ductal morphol-
ogy for ADO device occlusion but ADO device
was not available.
In our study, the rate of AEs, including high-
severity AEs (Levels 3, 4, and 5) was 1.9% in form
of ADO embolization and the child was referred tocardiac surgery without retrieval attempt. ADO
embolization is a well-known complication, espe-
cially in early experience of any cardiac center.
The reported rate varies from 0% to 3% [5,6,18–20].
In four patients in the current study, the PDA
occluders (ADO I) were implanted using venous
access only as the arterial line was not accessible.
Based on our experience we preserved this method
of implantation when an arterial line was not acces-
sible to avoid vasoconstriction of the duct tissue,
which may lead to underestimation of duct diame-
ters. However, this method is effective to avoid
postponing the procedure especially when PDA
closure is indicated in small children.
In the current study, one infant developed flow
acceleration (2.8 m/s) in the descending aorta on
a 6-month follow-up echocardiogram. This patient
continues to be followed as an outpatient without
further intervention for 2 years. However, no late
major AEs had occurred such as protrusion of
the occlusion device into the aorta or obstruction
to the left pulmonary artery, hemolysis, or
endocarditis.
A coil is still the preferred device for small PDAs
(<2.5 mm) [6,11,21]. In the present study, two types
of coil were used: the Nit Occlud PFM coil in four
patients and the Detachable Cook Coil in two. The
ADO was used in moderate and large PDA. The
Amplatzer VSD occluder was used in one infant
and ADO II in another with small tubular PDA.
The results documented in our series are in
accordancewith the results reportedby other inter-
ventional pediatric cardiac centers [6,17–19,22].Study limitations
Limitations of the present study include its ret-
rospective nature and the relatively small number
of patients. More studies with a larger number of
patients and younger patients are needed to ana-
lyze the safety and efficacy of transcatheter clo-
sure of PDA in this age group. Finally, the
learning curve for the technique of transcatheter
PDA closure in our institution was not conducted
in this study.Conclusion
With the current availability of devices for PDA
closure, transcatheter closure of PDA is consid-
ered safe and efficacious in small children weigh-
ing 610 kg with good mid-term outcome. The
procedure had a low rate of high-severity AEs
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